Follow The Filings

BLSM BlossomHill Therapeutics

BlossomHill Therapeutics earnings company data as of 7:25 PM ET 9/25

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q2 18 Sep EPS — -8.75 —
Rev — — —

Insider trades

Open-market buys and sales by BLSM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BLSM insider trades
  • $25.2M bought by 6 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Carl L Gordon Director
    Buy
    $10M 625,000 shares at $16.00 +30% to stake
    Traded Aug 10 Filed Aug 12
    ↗
  2. Vincent Paul Liptak General Counsel
    Buy
    $75K 4,700 shares at $15.89 +4.4% to stake
    Traded Aug 7–10 Filed Aug 10
    ↗
  3. Jason A Keyes CFO
    Buy
    $11K 700 shares at $16.00 New stake
    Traded Aug 10 Filed Aug 10
    ↗
  4. John P. Schmid Director
    Buy
    $96K 6,000 shares at $16.00 New stake
    Traded Aug 10 Filed Aug 10
    ↗
  5. Bihua Chen Director, +5 joint filers
    Buy
    $5M 312,500 shares at $16.00 +9.5% to stake
    Traded Aug 10 Filed Aug 10
    ↗

Also filed in the last 12 months, not counted as buying or selling: 14 conversions.

SEC filings

Recent issuer filings from EDGAR, 11 shown.

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13D — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13D — Filing Doc
8-K 5.03,8.01,9.01 Filing Doc
424B4 Filing Doc
S-1/A S-1/A: AMENDMENT NO. 1 Filing Doc
S-1 Filing Doc

Source: SEC EDGAR submissions, updated about 1 month ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.